Subtype
Soft Tissue Neoplasm of Uncertain Differentiation
CI-CAN-00001532Explore in graph →
Non-malignant74 active trials2 approved drugs38 evidence items
- NCIt
- C7148
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001532Explore in graph →
Clinical trials
241 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06453642 | Evaluation of a Simple-Prep Controlled Embolic(GPX) | active not recruiting | N/A | 114 | Fluidx Medical Technology, Inc.INDUSTRY | 3 | Mar 30, 2026 | clinicaltrials |
| NCT06789081 | GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02) | active not recruiting | Early Phase 1 | 1 | AHS Cancer Control AlbertaOTHER | 1 | Mar 23, 2026 |
| clinicaltrials |
| NCT04420975 | Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma | active not recruiting | Phase 1 | 14 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT03016819 | Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)(APROMISS) | recruiting | Phase 3 | 325 | Advenchen Laboratories, LLCINDUSTRY | 5 | Feb 25, 2026 | clinicaltrials |
| NCT07432932 | Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients(PANTHR-S) | recruiting | — | 800 | Royal Marsden NHS Foundation TrustOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06709495 | Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas | recruiting | Phase 1 / Phase 2 | 63 | David S Shulman, MDOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT03967834 | Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group(MIRAS) | recruiting | N/A | 400 | Institut Claudius RegaudOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT04390737 | Evaluate the Safety and Clinical Activity of HH2853 | recruiting | Phase 1 / Phase 2 | 254 | Haihe Biopharma Co., Ltd.INDUSTRY | 2 | Jan 30, 2026 | clinicaltrials |
| NCT07169344 | Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma(PROSARC-1) | recruiting | Phase 2 | 110 | Oslo University HospitalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07173972 | Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.(PROSARC-2) | recruiting | Phase 2 | 40 | Oslo University HospitalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06160310 | Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry) | recruiting | — | 300 | David M. RitterOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT04995003 | HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma | recruiting | Phase 1 | 25 | Baylor College of MedicineOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05467397 | Feasibility of [11C]Acetate-PET in LAM and TSC | active not recruiting | Phase 1 / Phase 2 | 7 | Brigham and Women's HospitalOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06889168 | Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)(LAMP-2) | recruiting | Phase 1 | 20 | Columbia UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT04690374 | Registry to Collect Health Information About Desmoplastic Small Round Cell Tumor | recruiting | — | 250 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT06849986 | IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)(TAIS) | recruiting | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06946225 | ACTengine® IMA203 Combined With mRNA-4203 | recruiting | Phase 1 | 15 | Immatics US, Inc.INDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06942442 | A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma | recruiting | Phase 2 | 47 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT07304856 | Role of Extracellular Vesicles as Biomarkers of Pulmonary Involvement in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex | recruiting | — | 80 | University of MilanOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT02869217 | Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors | active not recruiting | Phase 1 | 22 | University Health Network, TorontoOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT03618381 | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | active not recruiting | Phase 1 | 44 | Seattle Children's HospitalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT03099681 | An Observational Study on Epithelioid Sarcoma(EPISObs) | recruiting | — | 100 | Italian Sarcoma GroupNETWORK | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05296564 | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | recruiting | Phase 1 / Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07153887 | Vebreltinib for Advanced or Metastatic CCS | recruiting | Phase 2 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT06683846 | Ivonescimab in the Treatment of Multiple Advanced Tumors | recruiting | Phase 2 | 400 | Fudan UniversityOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT06277154 | MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | recruiting | Phase 2 | 148 | HRYZ Biotech Co.INDUSTRY | 1 | Jul 24, 2025 | clinicaltrials |
| NCT07066982 | Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas(BAH2573-103) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT06813417 | CAR T Therapy With GCAR1 for Relapsed Alveolar Soft Part Sarcoma(SPS-Q2) | active not recruiting | Early Phase 1 | 1 | University of CalgaryOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT06836505 | Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial. | recruiting | Phase 1 / Phase 2 | 10 | Sun Yat-Sen University Cancer CenterOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT06456359 | Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor(PAMSARC) | recruiting | Phase 2 | 28 | University Hospital HeidelbergOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06748872 | EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma(EPITOME-1015-I) | not yet recruiting | Phase 1 | 55 | Medigene AGINDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT02432560 | Safety and Durability of Sirolimus for Treatment of LAM(MIDAS) | recruiting | — | 600 | University of CincinnatiOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT03150914 | Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial(MILED) | active not recruiting | Phase 3 | 60 | University of CincinnatiOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT05727852 | Breath Analysis and Arterial Stiffness in Patients With Respiratory Diseases | enrolling by invitation | — | 400 | I.M. Sechenov First Moscow State Medical UniversityOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT06526897 | Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma | not yet recruiting | N/A | 1,582 | ECOG-ACRIN Cancer Research GroupNETWORK | 0 | Jul 30, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Mar 30, 2026source: clinicaltrials